Navigation Links
BIOLASE, Inc. Sued by Investor
Date:8/27/2013

SAN DIEGO and IRVINE, Calif., Aug. 27, 2013 /PRNewswire/ -- Shareholder rights attorneys at Robbins Arroyo LLP announce that an investor of BIOLASE, Inc. (NASDAQ: BIOL) ("BIOLASE") has filed a complaint in the U.S. District Court for the Central District of California.  The complaint alleges that the company and certain of its officers and directors violated the Securities Exchange Act of 1934 between January 7, 2013 and August 12, 2013 (the "Class Period").  BIOLASE develops, manufactures, and markets lasers in dentistry and medicine.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36754LOGO)

BIOLASE Accused of Making False and Misleading Statements

According to the complaint, certain BIOLASE officers and directors made false and/or misleading statements and/or failed to disclose information regarding the company's business, operations, and prospects.  Specifically, the complaint alleges that, throughout the Class Period, the company and certain of its officers and directors misrepresented and failed to disclose that: (i) contrary to claims by the company that its dental lasers were "becoming the standard of care" in the industry, BIOLASE's lasers were in use in only 5% of dental offices and disfavored by many dentists because of their high cost; (ii) the company's attempt to convert to a direct sales model in the United States was failing because of the high cost of the dental lasers; (iii) BIOLASE was financially impaired by its high debt burden and the terms of its lines of credit with Comerica Bank; and (iv) BIOLASE failed to generate cash from operations and was in default of its lines of credit with Comerica Bank.  As a result of these false and misleading statements and omissions, BIOLASE shares traded at artificially inflated prices during the Class Period.

BIOLASE Stock Price Drops on News of Revenue and Earnings Misses

On August 7, 2013, according to the complaint, BIOLASE announced its financial results for its second quarter 2013, reporting revenue of $14.2 million and a $.06 per share loss.  Both revenue and earnings numbers were significantly below the $15.69 million revenue and $.04 per share loss BIOLASE had led the market to expect.  Then, on August 13, 2013, BIOLASE issued a press release announcing that the company had violated the terms of its covenants with Comerica Bank.  On this news, BIOLASE shares fell to $1.81 on August 13, 2013, down nearly 80% from a Class Period high of $6.05 reached on April 29, 2013.

If you invested in BIOLASE and would like to discuss your shareholder rights, please contact attorney Darnell R. Donahue at (800) 350-6003, ddonahue@robbinsarroyo.com, or via the shareholder information form on the firm's website.

Robbins Arroyo LLP is a nationally recognized leader in securities litigation and shareholder rights law.  The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.  For more information, please go to http://www.robbinsarroyo.com.

Press release link: http://www.robbinsarroyo.com/shareholders-rights-blog/biolase-inc/

Attorney Advertising. Past results do not guarantee a similar outcome.  

Contact:
Darnell R. Donahue
Robbins Arroyo LLP
ddonahue@robbinsarroyo.com
(619) 525-3990 or Toll Free at (800) 350-6003
http://www.robbinsarroyo.com


'/>"/>
SOURCE Robbins Arroyo LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Shareholder Alert: Pomerantz Law Firm has filed a Class Action Against Biolase, Inc. and Certain Officers - BIOL
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. MAP Pharmaceuticals to Present at Upcoming Investor Conferences
4. Gen-Probe Withdraws from Previously Announced Investor Presentations
5. Watson Names Lisa DeFrancesco Vice President, Global Investor Relations
6. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
7. Hospira to Present at Upcoming Investor Conferences
8. Heska to Present at B. Riley Investor Conference
9. Parexel Invites Public To Listen To Live Webcast Of Its Investor Day May 31, 2012
10. B. Riley Revises Timing of STAAR Surgical Presentation at Investor Conference
11. CryoLife to Participate in 3rd Annual Benchmark Company, LLC One-on-One Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)...  IRIDEX Corporation (Nasdaq: IRIX ) today ... first quarter 2017 after the close of trading on ... host a corresponding conference call beginning at 2:30 p.m. ... in listening to the conference call may do so ... 326-3030 for international callers, using conference ID: 92158987.  A ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... The world-class ... support to bring their novel lifesaving device for the everyday use of parents ... sensors, specially designed to read a child’s vital signs, and detect unusual symptoms ...
(Date:4/24/2017)... Ill., and Waycross, Ga. (PRWEB) , ... April ... ... market leader and trusted advisor within the telehealth industry, announces the company’s VideoMedicine ... U.S. board-certified primary care providers. Available 24 hours a day, Quick Care provides ...
(Date:4/24/2017)... ... April 24, 2017 , ... According ... overdose deaths now claim the lives of 62 Americans each day.(1) Yet since ... drug manufacturers, distributors, pharmacies and prescribers by more than half.(2) Novus Medical ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... recognize elevated anxiety levels in people with addiction who are served by MAP’s ... a biosensing wearable device that monitors heart and breath rates to identify anxiety ...
(Date:4/24/2017)... ... 2017 , ... Pitavastatin, a relatively new statin, has relevance ... to have significant interactions with antiretroviral therapy (ART). Among people living with ... inflammation in the bloodstream. , While lowering cholesterol and dampening inflammation are beneficial ...
Breaking Medicine News(10 mins):